|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2000-6-1
|
|
pubmed:abstractText |
Selective estrogen receptor modulators (SERMs) are a new class of drugs that provide a new option for addressing the health challenges of postmenopausal women. This review discusses the proposed mechanism of action of SERMs and describes clinical findings on raloxifene, a SERM now available for treating and preventing osteoporosis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0891-1150
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
273-80
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10780099-Aged,
pubmed-meshheading:10780099-Calcitonin,
pubmed-meshheading:10780099-Diphosphonates,
pubmed-meshheading:10780099-Estrogen Replacement Therapy,
pubmed-meshheading:10780099-Female,
pubmed-meshheading:10780099-Humans,
pubmed-meshheading:10780099-Middle Aged,
pubmed-meshheading:10780099-Osteoporosis,
pubmed-meshheading:10780099-Postmenopause,
pubmed-meshheading:10780099-Raloxifene,
pubmed-meshheading:10780099-Risk Factors,
pubmed-meshheading:10780099-Selective Estrogen Receptor Modulators
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Raloxifene: a new choice for treating and preventing osteoporosis.
|
|
pubmed:affiliation |
Department of Endocrinology, Cleveland Clinic, OH 44195, USA. licataa@ccf.org
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|
